Gritstone Bio Retained Earnings (Accumulated Deficit) 2017-2024 | GRTSQ
Gritstone Bio retained earnings (accumulated deficit) from 2017 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Gritstone Bio Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2023 |
$-660 |
| 2022 |
$-521 |
| 2021 |
$-401 |
| 2020 |
$-326 |
| 2019 |
$-221 |
| 2018 |
$-126 |
| 2017 |
$-62 |
| 2016 |
$-20 |
Gritstone Bio Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024-06-30 |
$-723 |
| 2024-03-31 |
$-700 |
| 2023-12-31 |
$-660 |
| 2023-09-30 |
$-629 |
| 2023-06-30 |
$-590 |
| 2023-03-31 |
$-555 |
| 2022-12-31 |
$-521 |
| 2022-09-30 |
$-490 |
| 2022-06-30 |
$-460 |
| 2022-03-31 |
$-430 |
| 2021-12-31 |
$-401 |
| 2021-09-30 |
$-372 |
| 2021-06-30 |
$-343 |
| 2021-03-31 |
$-318 |
| 2020-12-31 |
$-326 |
| 2020-09-30 |
$-299 |
| 2020-06-30 |
$-273 |
| 2020-03-31 |
$-247 |
| 2019-12-31 |
$-221 |
| 2019-09-30 |
$-193 |
| 2019-06-30 |
$-166 |
| 2019-03-31 |
$-145 |
| 2018-12-31 |
$-126 |
| 2018-09-30 |
$-109 |
| 2018-06-30 |
|
| 2018-03-31 |
|
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2016-12-31 |
$-20 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.016B |
|
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
|
